Molecular mechanisms involved in hormone resistance of prostate cancer;Mécanismes moléculaires impliqués dans l'hormonorésistance du cancer de la prostate

Bulletin du Cancer

Volumn 91, Issue 10, 2004, Pages 747-757

  Cabrespine, Aurélie ^a,b   Guy, Laurent ^c   Chollet, Philippe ^a,b   Debiton, Éric ^a,b   Bay, Jacques Olivier ^a  

^a CENTRE JEAN PERRIN   (France)

^b INSERM   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Androgen receptor; Cytokines; Growth factors; Hormone refractory; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; FLUTAMIDE; GROWTH FACTOR; INTERLEUKIN 6; MEDROXYPROGESTERONE; NILUTAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID 5ALPHA REDUCTASE; STEROID HORMONE;

CANCER GROWTH; CANCER THERAPY; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE MUTATION; HORMONE DEPENDENCE; HORMONE RESISTANCE; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR MECHANICS; NEUROSECRETORY CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SENSITIVITY ANALYSIS;

ANDROGEN ANTAGONISTS; ANDROGENS; APOPTOSIS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GROWTH SUBSTANCES; HUMANS; INTERLEUKINS; MALE; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; NEUROSECRETORY SYSTEMS; ORCHIECTOMY; PHENOTYPE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; RECEPTORS, GROWTH FACTOR; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE; TRANSPLANTATION, HETEROLOGOUS;

EID: 9244240304     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Hill C, Doyon F. Frequency of cancer in France: 2004 update. Bull Cancer 2004; 91: 9-14.
2. Zilliacus J, Wright AP, Carlstedt-Duke J, Gustafsson JA. Structural determinants of DNA-binding specificity by steroid receptors. Mol Endocrinol 1995; 9: 389-400.
3. Veldscholte J, Berrevoets CA, Zegers ND, Van Der Kwast TH, Grootegoed JA, Mulder E. Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 1992; 31: 7422-30.
4. Culig Z, Hobisch A, Bartsch G, Klocker H. Androgen receptor-an update of mechanisms of action in prostate cancer. Urol Res 2000; 28: 211-9.
5. Huggins C, Hodges CV. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
6. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991-8.
7. Labrie F, Dupont A, Belanger A, Giguere M, Lacoursiere Y, Emond J, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 1985; 23: 833-41.
8. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 1998; 58: 5310-4.
9. Ruizeveld De Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994; 144: 735-46.
10. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997; 57: 2321-4.
11. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet 1995; 9: 401-6.
12. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-9.
13. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000; 164: 1992-5.
14. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-8.
15. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944-9.
16. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992; 41: 665-9.
17. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995; 76: 1428-34.
18. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59: 2511-5.
19. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nature Med 2000; 6: 703-6.
20. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994; 91: 11733-7.
21. Yeh CC, Lee C, Dahiya R. DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem Biophys Res Commun 2001; 285: 409-13.
22. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002; 23: 175-200.
23. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-9.
24. Fujimoto N, Mizokami A, Harada S, Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology 2001; 58: 289-94.
25. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998; 95: 7379-84.
26. Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA 2003; 100: 5124-9.
27. Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003; 22: 2466-77.
28. Labrie F, Dupont A, Belanger A, St-Arnaud R, Giguere M, Lacourciere Y, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 1986; 7: 67-74.
29. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-8.
30. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001; 61: 6276-80.
31. Mitsiades CS, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin Investig Drugs 2001; 10: 1099-115.
32. Deocampo ND, Huang H, Tindall DJ. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol 2003; 28: 145-53.
33. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997; 8: 45-62.
34. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996; 81: 411-20.
35. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999; 91: 1758-64.
36. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003; 63: 3575-84.
37. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001; 166: 1514-9.
38. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 1918-25.
39. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med 1999; 5: 280-5.
40. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 6841-5.
41. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999; 96: 5458-63.
42. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch Jr G, Klocker H, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000; 191: 239-44.
43. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999; 41: 127-33.
44. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-6.
45. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58: 4640-5.
46. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002; 277: 7076-85.
47. Murata T, Noguchi PD, Puri RK. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol 1996; 156: 2972-8.
48. Lee SO, Lou W, Hou M, Onate SA, Gao AC. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 2003; 22: 7981-8.
49. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: 263-73.
50. Craft N, Chhor C, Tran C, Belldegrun A, Dekernion J, Witte ON, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999; 59: 5030-6.
51. Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an endocrine marker. Pathol Res Pract 1989; 185: 373-80.
52. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993; 71: 3952-65.
53. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45: 586-92 [discussion 592].
54. Krijnen JL, Janssen PJ, Ruizeveld De Winter JA, Van Krimpen H, Schroder FH, Van Der Kwast TH. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993; 100: 393-8.
55. Di Sant'agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001; 12(Suppl 2): S135-40.
56. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, et al. Alteration of the tumor suppressor gene p5 3 in a high fraction of hormone refractory prostate cancer. J Urol 1995; 154: 414-21.
57. Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, et al. Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene 2002; 21: 153-7.
58. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, Shemshedini L. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 2001; 276: 38472-9.
59. Wesrin P, Stattin P, Damber JE, Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995; 146: 1368-75.
60. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4.
61. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999; 5: 2891-8.
62. Kolar Z, Murray PG, Scott K, Harrison A, Vojtesek B, Dusek J. Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol 2000; 53: 15-8.
63. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002; 94: 980-6.
64. Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, et al. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer 2002; 95: 1864-8.
65. Santen RJ, Perroni GR, Fisch MJ, Myers CE, Theodorescu D, Cohen RB. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer 2001; 92: 2095-101.
66. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001; 28: 8-15.
67. Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, Shiina H. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002; 168: 2444-50.